Skip to main content


Fig. 7 | Journal of Experimental & Clinical Cancer Research

Fig. 7

From: Integrated omics-based pathway analyses uncover CYP epoxygenase-associated networks as theranostic targets for metastatic triple negative breast cancer

Fig. 7

Pathway deregulation scoring (PDS) reveals targetable vulnerabilities in TNBC tissues with high CYP epoxygenase expression. a Hierarchical clustering of all curated pathways differentiates CYP epoxygenase overexpressing HER2+, ER+/PR+/HER2−/TPBC and TNBC tumors. b PDS of all TNBC samples (N = 200) identify a subgroup (TNBC-subtype I) with significantly higher scores for FA (arachidonic acid) metabolism and metastasis-related pathways. c Higher CYP epoxygenase expression is correlated with lower overall percentage survival in TNBC Subtype I patients stratified from the TCGA and METABRIC cohorts. d Eight TNBC samples subjected to oxylipin metabolomics and proteomics analyses consistently show upregulation of CYP epoxygenase-related gene signatures as well as metastasis-related signatures observed from the TCGA cohort. Comparatively overexpressed proteins in tumor samples were subjected to further analysis of canonical pathways using the Ingenuity Pathways Analysis (IPA) database. The canonical pathway with –log(p-value) ≥ 1.3 (representing P < 0.05) was set as a statistical significance in IPA analysis. The black dotted line indicates –log value of 1.3 as the threshold. Specimens labeled TNBC1–3 are stage IA,TNBC6–8 are stage IIB, and TNBC4–5 are stage IIIA tumor samples

Back to article page